ArticleInvestigational new drugs2022

Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.

Stergios J Moschos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.